

## **Northern Ireland Executive consulting on NICE TA - Elbasvir-grazoprevir for treating chronic hepatitis C, and whether it is applicable in Northern Ireland**

Thank you for asking us to comment on this. The BHIVA/BASHH Consultation Group on Hepatitis Topics (S Bhagani, E Foley, R James, R Kulasegaram, M Nelson and L Waters) were consultees at the NICE TA and are in agreement with the NICE appraisal and approval within its license for the treatment of HCV.

This would be equally applicable to Northern Ireland, and the availability of Grazoprevir-Elbasvir for Genotype1 and 4 patients as an additional treatment to the already approved DAAs will hopefully drive down prices and ensure that more patients will have access to treatment. Furthermore, Grazoprevir-elbasvir is a very useful option for HCV treatment in patients with renal failure (including those on dialysis) and patients unable to take or tolerate ribavirin.

British HIV Association (BHIVA) and the British Association for Sexual Health and HIV (BASHH)